Publication
Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerTransitional Cell Carcinomacivic_curation1.00
- drugAfatinibcivic_curation1.00
- geneERBB3civic_curation1.00
- variantERBB3 G284Rcivic_curation1.00
- variantERBB3 R103Gcivic_curation1.00
- variantERBB3 V104Mcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27044931
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ERBB2 Amplification1 | ||||||||
| Afatinib | Transitional Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 2 | submitted | EID7810In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or… (full text at CIViC) PMID 27044931 · Choudhury et al., 2016 · Open in CIViC | civic |
| ERBB3 G284R1 | ||||||||
| Afatinib | Transitional Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1748In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or… (full text at CIViC) PMID 27044931 · Choudhury et al., 2016 · Open in CIViC | civic |
| ERBB3 R103G1 | ||||||||
| Afatinib | Transitional Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1747In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or… (full text at CIViC) PMID 27044931 · Choudhury et al., 2016 · Open in CIViC | civic |
| ERBB3 V104M1 | ||||||||
| Afatinib | Transitional Cell Carcinoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1746In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or… (full text at CIViC) PMID 27044931 · Choudhury et al., 2016 · Open in CIViC | civic |